|
|
| Name: | Bryan Roth |
| Email: | bryan_roth@med.unc.edu |
| Hometown: | |
| Title: | Big Kahuna |
|
|
|
Publications:
Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004 Nov 19;306(5700):1380-3
Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J. Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. Neuron, Vol 45, Issue 4, 3 February 2005
Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL. Identification of the Molecular Mechanisms by Which the Diterpenoid Salvinorin A Binds to kappa-Opioid Receptors. Biochemistry. 2005 Jun 21;44(24):8643-8651
Setola V, Dukat M, Glennon RA, Roth BL. Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor. Mol Pharmacol. 2005 Jul;68(1):20-33. Epub 2005 Apr 14
Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth BA, Roth BL. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Gaq-coupled GPCRs . J. Biol. Chem. published 9 June 2004, 10.1074/jbc.M404673200
Xia Z, Gray JA, Compton-Toth BA, Roth BL. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem 2003 Jun 13;278(24):21901-8. Epub 2003 Apr 07
Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 2002 Sep 3;99(18):11934-9. Epub 2002 Aug 21
Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002 Mar 29;277(13):11441-9. Epub 2002 Jan 18
Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F. Studies toward the pharmacophore of Salvinorin A. a potent kappa opiod receptor agonist. J Med Chem. 2005 Jan 27;48(2):345-8
Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, Leahy P, Bruning JC, Roth BL. p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.. Proc Natl Acad Sci U S A. 2006 Mar 10; [Epub ahead of print]
Kozikowski AP, Roth B, Tropsha A. Why Academic Drug Discovery Makes Sense. Science. 2006 Sep 1;313(5791):1235-6
Roth BL, Sheffler DJ, Kroeze WK. Opinion: Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004 Apr;3(4):353-9
Armbruster BN, Roth BL. Mining the receptorome. J. Biol. Chem, 10.1074/jbc.R400030200
Sheffler DJ, Roth BL. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003 Mar;24(3):107-9
JA Gray and BL Roth. A last GASP for GPCR's?. Science 297: 529-531,2002
Kroeze, W.K., K. Kristiansen and BL Roth. Molecular biology of serotonin receptors: structure and function at the molecular level. Curr Top Med Chem 2:507-528, 2002
Roth BL. Neuronal Signal Transduction Pathways: Wasteland or the Promised Land? Science (STKE). http://www.stke.org/cgi/content/full/OC_sigtrans;2000/45/pe1
Roth BL, Willins D. What's all the RAVE about receptor internalization?. Neuron. 23:629-631
O'Sullivan GJ, Roth BL, Kinsella A, Waddington JL. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.. Eur J Pharmacol. 2004 Feb 23;486(3):273-80
Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther. 2004 Mar;308(3):1197-203. Epub 2004 Jan 08
Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 2003 Dec 15;116(Pt 24):4867-9
O'Connor,KA and Roth, BL. Screening the receptorome for plant-derived psychoactive compounds.
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun;63(6):1223-9
Setola, V and Roth, BL. Elucidating the atomic determinants for the interaction of the valvulopathic drug norfenfluramine with its molecular target: the serotonin 5-HT2B receptor (in preparation).
Chang-Fong J, Rangisetty JB, Dukat M, Setola V, Raffay T, Roth B, Glennon RA. 1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands.. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1961-4
Pullagurla MR, Dukat M, Setola V, Roth B, Glennon RA. N1-benzenesulfonylgramine and N1-benzenesulfonylskatole: novel 5-HT6 receptor ligand templates.. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3355-9
Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF. Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33
Setola V, Roth BL. Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol Pharmacol. 2003 Dec;64(6):1277-8
|
|
| | |
